



LivaNova

Health innovation that matters

LivaNova Education Series: **Seizing the Epilepsy Opportunity**

Intended for Investor Use Only - Not Intended for Use by Patients or HCPs

Stifel had no involvement in the preparation of this presentation and, accordingly, makes no representation or warranty as to the accuracy or completeness of any of the information or data included therein and expressly disclaims any and all liability relating to or resulting from use of this presentation.

Safe Harbor

Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this presentation, including the risks relating to the COVID-19 pandemic or settlement of litigation, as well as those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. All information in this presentation is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this presentation to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this presentation.

Positioning LivaNova to Realize its Full Value

Consistently deliver growth, pipeline and profitability

Core Growth

Focus on portfolio optimization to support leadership positions in underserved markets

- Expand and enhance commercial initiatives for U.S. Epilepsy
- Forecast at least 30% ACS growth in 2020 and at least 20% in 2021

Pipeline Execution

Multiple existing and pipeline initiatives to accelerate growth

- Achieve key study milestones in RECOVER and ANTHEM HFReF
- Continued progress on next generation Heart-Lung Machine

Operational Excellence

Drive margin expansion

- Expand Operating margin through cost discipline
- Drive improvement in free cash flow generation



VNS Therapy for Epilepsy: Market Size



¹CDC "National and State Estimates of the Numbers of Adults and Children with Active Epilepsy —United States, 2015" (Zack, Kobau); Applied 2015 estimate (3.4MM) as a portion of 2015 population (1.1%) to 2018 US population (US Census Bureau)

²National Association of Epilepsy Centers (Gummit, Labiner, et al.), 70%

³National Association of Epilepsy Centers (Gummit, Labiner, et al.); European Journal of Epilepsy (Lang, Grell, et al.) and LivaNova data.

⁴Epilepsia (Helmers, Thurman, et al.), ~5% and American Epilepsy Society, National Institute of Neurological Disorders and Stroke (30%)




VNS Therapy Addresses the Needs of DRE Patients

- **Seizure reduction** that continues to improve over time¹
- **Quality of life improvements**, independent of seizure control²
- **Decreased healthcare** utilization and costs³
- **Decreased seizure severity/postictal period**^{4,5}
- **Nonpharmacological side effects** that typically diminish over time^{6,7}
- **Decrease in the number of depressive episodes**⁸
- **Positive Impact on SUDEP rates**⁹
- **Pediatric patients increased cognitive function**, including increased memory and verbal skills¹⁰




1. Elliott RE, et al. Epilepsy Behav 2011;20(3):478-483. 2. Klinkenberg S, et al. Clin Neurol Neurosurg 2012;114(4):336-340. 3. Helmers SL, et al. Epilepsy Behav 2011;22(2):370-375. 4. Tubbs RS, et al. J Neurosurg 2005;102(Suppl 2):213-217. 5. Vonck K, et al. Epilepsy Behav 2010;19(2):182-185. 6. Morris GL III, Mueller WM. Neurology 1999;53(7):1731-1735. 7. Ben-Menachem E. J Clin Neurophysiol 2001;18(5):415-418. 8. Schmidt D., The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. EPILEPSY_RES, 2002, 50(1-2). 9. Annegers JF, et al. Epilepsia 2000;41:549-553. 2. Morris GL, et al. Neurology 2013;81:1453-9.

25 Years of VNS Therapy Impact



Commercial Elevation with the Comprehensive Epilepsy Centers

VNS Site-of-Care Distribution (Number of Centers)



LivaNova CEC Team

Case Manager
"The Coordinator"

Key Account Manager
"The Quarterback"



Medical Science Liaison
"The Scientist"

Clinical Nurse Education Specialist
"The Trainer"

8 Teams in place today
3 new Teams to deploy in 2021

45 additional Sales and Clinical Professionals

Seizing the Epilepsy Opportunity

Summary

- DRE is a large, underserved market
- VNS meets key patient and physician needs where other DRE therapy options are limited
- VNS has an established 25-year history of extensive patient utilization and efficacy
- LivaNova has a large field sales team with national reach into Community and CEC health systems throughout the U.S.
- We will accelerate our performance by executing a focused strategy to expand our presence in key, high-growth Level 3 & 4 CECs




LivaNova

Health innovation that matters

LivaNova

Health innovation that matters

Q&A



1. INTENDED USE / INDICATIONS

- ***Epilepsy (US)***—The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

2. CONTRAINDICATIONS

- ***Vagotomy***—The VNS Therapy System cannot be used in patients after a bilateral or left cervical vagotomy.
- ***Diathermy***—Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy on patients implanted with a VNS Therapy System. Diagnostic ultrasound is not included in this contraindication.